Sanofi
Type 1 diabetes market value to double by 2023
March 19, 2015Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …
Sanofi diabetes drug fails to show cardio disease benefit
March 19, 2015Research and Development, Sales and Marketing ACS, Lixisenatide, Lyxumia, Sanofi, cardio, diabetes
A Phase IIIb study of Sanofi’s diabetes drug lixisenatide has shown it is no better or worse than a placebo …
Sanofi affiliate to supply 37 million vaccines
March 17, 2015Manufacturing and Production, Sales and Marketing GAVI, Sanofi, Sanofi Pasteur, Shantha Biotechnics, shan5, vaccines
Sanofi’s vaccines division Sanofi Pasteur has confirmed its affiliate Shantha Biotechnics in India has delivered the first 400,000 doses of …
Sanofi and Amgen cholesterol drugs shine
March 16, 2015Sales and Marketing Amgen, PCSK9, Repatha, Sanofi, alirocumab, evolocumab, praluent
Two large Phase III studies of Sanofi’s Praluent and Amgen’s Repatha have found the biologic cholesterol-lowering drugs are more effective …
Oncologists say CDF cuts will compromise treatment
March 10, 2015Sales and Marketing CDF, Jevtana, NHS, NICE, Sanofi, cabazitaxel, doctors.net, m3
Oncologists believe cutting drugs from the Cancer Drugs Fund won’t save the NHS money and will worsen patient outcomes according …
Sanofi names audit committee chairman
March 10, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Robert Castaigne, Sanofi
Sanofi has looked to its own board to fulfil the role of chairman as it names Robert Castaigne chairman of …
Ousted Sanofi boss finds role at PureTech
February 27, 2015Sales and Marketing Bayer, Sanofi, Viehbacher, baumann, brandicourt, pott, puretech
US science and technology R&D company PureTech has appointed the former Sanofi chief executive Christopher Viehbacher to its board. Viehbacher …
Bayer justifies Brandicourt’s ‘golden handshake’
February 27, 2015Medical Communications, Sales and Marketing Bayer, CEO, Sanofi, dekkers, olivier brandicourt, payments, wages
Bayer has confirmed that Sanofi’s justification for the controversial starter package it is giving to the German firm’s Olivier Brandicourt …
Sanofi sees FDA approval for diabetes drug
February 26, 2015Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4
US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …
Sanofi confirms new chief executive
February 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Chris Viehbacher, Sanofi, praluent
Bayer chairman Olivier Brandicourt has been named as Sanofi’s new chief executive to replace Chris Viehbacher who was ejected from …
Sanofi enters autoimmune diseases pact with Lead Pharma
February 18, 2015Research and Development, Sales and Marketing Sanofi, autoimmune, biox, lead pharma, psoriasis
Sanofi is to collaborate with Dutch biotech firm Lead Pharma to develop treatments for autoimmune diseases. The companies will work …
Boehringer and Sanofi admit to code breaches
February 13, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, PMCPA, Sanofi, afatinib, giotrif
Sanofi and Boehringer Ingelheim have both admitted to breaching the ABPI Code of Practice, with Sanofi set to be publicly …
Sanofi makes gene therapy move
February 13, 2015Research and Development, Sales and Marketing Genzyme, Sanofi, Voyager Therapeutics, gene therapy, merger
Sanofi has signalled its intent to develop gene therapy treatments for nerve diseases through a $745 million deal with US …
Sanofi sales lifted by diabetes and rare diseases
February 6, 2015Sales and Marketing Genzyme, Lantus, Sanofi, diabetes, financials, insulin glargine, praluent, q4
Sanofi racked up €7.4 billion in sales in the fourth quarter of 2014 according to the company’s latest financials report. …
Half of UK population will get cancer
February 4, 2015Research and Development, Sales and Marketing CDF, CRUK, Cancer, Jevtana, Sanofi, cabazitaxel
New figures from Cancer Research UK (CRUK) suggest that one in two people will develop cancer at some point in …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
